<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="./PMC5854648/results/search/disease/results.xml">
  <result pre="isoform, PDE4, is overactive in chronic relapsing inflammatory skin diseases:" exact="psoriasis" post="and eczema/atopic dermatitis, and in several cancers. East Indian"/>
  <result pre="anti-inflammatory properties. Here, we report that 75% of pediatric eczema/atopic" exact="dermatitis" post="patients treated with topical EISO formulations achieved a &amp;gt;50%"/>
  <result pre="Eczema Area and Severity Index score. EISO treatment of a" exact="psoriasis" post="model reduced PDE4 expression and reversed histopathology. EISO directly"/>
  <result pre="an attractive natural therapeutic for chronic and acute inflammatory disorders." exact="psoriasis" post="atopic dermatitis eczema cancer phosphodiesterase skin organoid anti-inflammatory anti-proliferative"/>
  <result pre="attractive natural therapeutic for chronic and acute inflammatory disorders. psoriasis" exact="atopic dermatitis" post="eczema cancer phosphodiesterase skin organoid anti-inflammatory anti-proliferative fig-count: table-count:"/>
  <result pre="natural therapeutic for chronic and acute inflammatory disorders. psoriasis atopic" exact="dermatitis" post="eczema cancer phosphodiesterase skin organoid anti-inflammatory anti-proliferative fig-count: table-count:"/>
  <result pre="for chronic and acute inflammatory disorders. psoriasis atopic dermatitis eczema" exact="cancer" post="phosphodiesterase skin organoid anti-inflammatory anti-proliferative fig-count: table-count: equation-count: ref-count:"/>
  <result pre="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Psoriasis (PS) and" exact="atopic dermatitis" post="(AD) are chronic or recurrent inflammatory dermatologic disorders that"/>
  <result pre="table-count: equation-count: ref-count: page-count: word-count: Introduction Psoriasis (PS) and atopic" exact="dermatitis" post="(AD) are chronic or recurrent inflammatory dermatologic disorders that"/>
  <result pre="treatment of inflammatory skin disorders as has been reported for" exact="psoriasis" post="( Sharma et al., 2017) and acne ( Moy"/>
  <result pre="The therapeutic potential of PDE4 inhibition in diseases such as" exact="chronic obstructive pulmonary disease" post="(COPD), cystic fibrosis (CF) and asthma, has long been"/>
  <result pre="inhibition in diseases such as chronic obstructive pulmonary disease (COPD)," exact="cystic fibrosis" post="(CF) and asthma, has long been appreciated, with PDE4B"/>
  <result pre="and total PDE and NF-κB activation, in skin, blood, and" exact="lung cancer" post="models. These results suggest that EISO may be a"/>
  <result pre="total PDE and NF-κB activation, in skin, blood, and lung" exact="cancer" post="models. These results suggest that EISO may be a"/>
  <result pre="5% (v/v) FBS (Invitrogen, Carlsbad, CA, United States). THP-1 human" exact="acute monocytic leukemia" post="cells were maintained in RPMI (Invitrogen)/5% (v/v) FBS. All"/>
  <result pre="(v/v) FBS (Invitrogen, Carlsbad, CA, United States). THP-1 human acute" exact="monocytic leukemia" post="cells were maintained in RPMI (Invitrogen)/5% (v/v) FBS. All"/>
  <result pre="FBS (Invitrogen, Carlsbad, CA, United States). THP-1 human acute monocytic" exact="leukemia" post="cells were maintained in RPMI (Invitrogen)/5% (v/v) FBS. All"/>
  <result pre="). FIGURE 1 Phase 2 Clinical Trials for treatment of" exact="atopic dermatitis" post="(AD) and psoriasis. (A) Percentage change in patients’ EASI"/>
  <result pre="FIGURE 1 Phase 2 Clinical Trials for treatment of atopic" exact="dermatitis" post="(AD) and psoriasis. (A) Percentage change in patients’ EASI"/>
  <result pre="Blanchard et al., 2014). A549 cells were used as a" exact="lung cancer" post="model, since lung cancer is a frequent comorbidity in"/>
  <result pre="et al., 2014). A549 cells were used as a lung" exact="cancer" post="model, since lung cancer is a frequent comorbidity in"/>
  <result pre="A549 cells were used as a lung cancer model, since" exact="lung cancer" post="is a frequent comorbidity in COPD and therefore share"/>
  <result pre="cells were used as a lung cancer model, since lung" exact="cancer" post="is a frequent comorbidity in COPD and therefore share"/>
  <result pre="the EISO attenuation of LPS-stimulated total cellular cAMP hydrolysis activity," exact="suppression" post="of total cellular cAMP PDE activity in EISO treated,"/>
  <result pre="Gallo, 2012), we assessed PDE4 expression and distribution in this" exact="psoriasis" post="model as well ( Figure 5 ). After 4"/>
  <result pre="was dose-dependently suppressed by EISO to approaching 90%. The robust" exact="suppression" post="key cytokine-related factors production indicates that the ability of"/>
  <result pre="for treatment of AD ( Browning et al., 2017) and" exact="psoriasis" post="( Sharma et al., 2017) was found to be"/>
  <result pre="substantial anti-inflammatory properties in skin models that are linked to" exact="suppression" post="of prostaglandin and thromboxane production and cytokine/chemokine expression ("/>
  <result pre="by IHC ( Figure 5 ) supports the observed EISO-mediated" exact="suppression" post="of PDE4 transcription and indicates that EISO can suppress"/>
  <result pre="C. Wollenberg A. et al. ( 2013). Management of difficult-to-treat" exact="atopic dermatitis." post="J. Allergy Clin. Immunol. Pract. 1 142– 151. 10.1016/j.jaip.2012.09.002"/>
  <result pre="Integrin-linked kinase as a target for ERG-mediated invasive properties in" exact="prostate cancer" post="models. Carcinogenesis 33 2558– 2567. 10.1093/carcin/bgs285 23027626 Bjorgo E."/>
  <result pre="kinase as a target for ERG-mediated invasive properties in prostate" exact="cancer" post="models. Carcinogenesis 33 2558– 2567. 10.1093/carcin/bgs285 23027626 Bjorgo E."/>
  <result pre="expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe" exact="psoriasis" post="vulgaris. Br. J. Dermatol. 174 136– 145. 10.1111/bjd.14034 26189551"/>
  <result pre="neuroendocrine characteristics by prostate tumor cells is reversible: implications for" exact="prostate cancer" post="progression. Cancer Res. 59 3821– 3830. 10447001 Czarnowicki T."/>
  <result pre="characteristics by prostate tumor cells is reversible: implications for prostate" exact="cancer" post="progression. Cancer Res. 59 3821– 3830. 10447001 Czarnowicki T."/>
  <result pre="( 2005). Chemopreventive effects of various concentrations of α-santalol on" exact="skin cancer" post="development in CD-1 mice. Eur. J. Cancer Prev. 14"/>
  <result pre="2005). Chemopreventive effects of various concentrations of α-santalol on skin" exact="cancer" post="development in CD-1 mice. Eur. J. Cancer Prev. 14"/>
  <result pre="T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic" exact="atopic dermatitis." post="J. Allergy Clin. Immunol. 130 1344– 1354. 10.1016/j.jaci.2012.07.012 22951056"/>
  <result pre="augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic" exact="liver disease." post="Am. J. Physiol. Gastrointest. Liver Physiol. 295 G718– G724."/>
  <result pre="K. E. Krueger J. G. ( 2011). Contrasting pathogenesis of" exact="atopic dermatitis" post="and psoriasis–part I: clinical and pathologic concepts. J. Allergy"/>
  <result pre="E. Krueger J. G. ( 2011). Contrasting pathogenesis of atopic" exact="dermatitis" post="and psoriasis–part I: clinical and pathologic concepts. J. Allergy"/>
  <result pre="eczema area and severity index (EASI): assessment of reliability in" exact="atopic dermatitis." post="EASI Evaluator Group. Exp. Dermatol. 10 11– 18. 10.1034/j.1600-0625.2001.100102.x"/>
  <result pre="K. Chamlin S. L. ( 2008). The socioeconomic impact of" exact="atopic dermatitis" post="in the United States: a systematic review. Pediatr. Dermatol."/>
  <result pre="Chamlin S. L. ( 2008). The socioeconomic impact of atopic" exact="dermatitis" post="in the United States: a systematic review. Pediatr. Dermatol."/>
  <result pre="( 2012). PDE4: a novel target in the treatment of" exact="chronic obstructive pulmonary disease." post="Clin. Pharmacol. Ther. 91 134– 142. 10.1038/clpt.2011.266 22130119 Miotla"/>
  <result pre="role of the cAMP effectors Epac and PKA: implications in" exact="chronic obstructive pulmonary disease." post="PLoS One 7: e31574. 10.1371/journal.pone.0031574 22363678 Oliva A. A."/>
  <result pre="nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of" exact="atopic dermatitis" post="(AD) in children and adults. J. Am. Acad. Dermatol."/>
  <result pre="phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic" exact="dermatitis" post="(AD) in children and adults. J. Am. Acad. Dermatol."/>
  <result pre="et al. ( 2013). Phosphodiesterase-4 promotes proliferation and angiogenesis of" exact="lung cancer" post="by crosstalk with HIF. Oncogene 32 1121– 1134. 10.1038/onc.2012.136"/>
  <result pre="al. ( 2013). Phosphodiesterase-4 promotes proliferation and angiogenesis of lung" exact="cancer" post="by crosstalk with HIF. Oncogene 32 1121– 1134. 10.1038/onc.2012.136"/>
  <result pre="Antineoplastic effects of α-santalol on estrogen receptor-positive and estrogen receptor-negative" exact="breast cancer" post="cells through cell cycle arrest at G2/M phase and"/>
  <result pre="effects of α-santalol on estrogen receptor-positive and estrogen receptor-negative breast" exact="cancer" post="cells through cell cycle arrest at G2/M phase and"/>
  <result pre="P. ( 2012). Apremilast mechanism of action and application to" exact="psoriasis" post="and psoriatic arthritis. Biochem. Pharmacol. 83 1583– 1590. 10.1016/j.bcp.2012.01.001"/>
  <result pre="2012). Apremilast mechanism of action and application to psoriasis and" exact="psoriatic arthritis." post="Biochem. Pharmacol. 83 1583– 1590. 10.1016/j.bcp.2012.01.001 22257911 Schafer P."/>
  <result pre="and P-selectin on endothelium in situ in patients with erythroderma," exact="mycosis" post="fungoides and atopic dermatitis. J. Cutan. Pathol. 27 436–"/>
  <result pre="endothelium in situ in patients with erythroderma, mycosis fungoides and" exact="atopic dermatitis." post="J. Cutan. Pathol. 27 436– 440. 10.1034/j.1600-0560.2000.027009436.x 11028813 Smith"/>
  <result pre="( 2013). Phosphodiesterase 4 inhibition in the treatment of psoriasis," exact="psoriatic arthritis" post="and other chronic inflammatory diseases. Dermatol. Ther. 3 1–"/>
  <result pre="2013). Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic" exact="arthritis" post="and other chronic inflammatory diseases. Dermatol. Ther. 3 1–"/>
  <result pre="pathogenic mechanisms and pathways in the development of COPD and" exact="lung cancer." post="Expert Opin. Ther. Targets 15 439– 456. 10.1517/14728222.2011.555400 21284573"/>
 </snippets>
</snippetsTree>
